LP-184 May Expand Options for Pancreatic Cancers With DDR Defects

1 year ago 38

In an interview with Targeted Oncology, Igor Astsaturov, MD, PhD, discussed what led to the development of LP-184 and explained how the agent will be evaluated moving forward.

1. Homepage
2. category-label-
3. LP-184 May Expand Options for Pancreatic Cancers With DDR Defects